

IFW

Application No. 10/735,963
Sorensen et al.
Filed December 15, 2003



Attorney Docket No.: 6567.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Sorensen et al.

Confirmation No.: 3391

Serial No.: 10/735,963

Group Art Unit: 1614

Filed: December 15, 2003

Examiner: To be assigned

For: Substituted Homopiperidine, Piperidine or Pyrrolidine Derivatives

AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed November 16, 2004, having a two month period for response set to expire January 16, 2004, with extensions of time available under 37 CFR §1.136(a), Applicant timely submits the following Amendment. Applicant also encloses herewith an initial computer readable form (CRF) copy of the sequence listing and an initial paper copy. Applicant states the content of the sequence listing information recorded in the CRF is identical to the written sequence listing and includes no new matter.

Applicant believes no fee is necessary to timely file this paper. However, should any petition or fee be required for timely filing of this Amendment, Applicant hereby petitions for such Extension of Time and hereby grants authorization to charge Deposit Account No. 14-1447, in the name of Novo Nordisk, Inc., for any such required fee.